References
- ALOYAGI, Y., KOBUNAI, T., UTSUGI, T., OH-HARA, T. and YAMADA, Y., 1999, In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II. Japanese Journal of Cancer Research, 90, 578–587.
- AZUMW, R. and URAKAW A., 1997, Simultaneous determination of a novel anticancer drug, TAS-103, and its N-demethylated metabolite in monkey plasma by high-performance liquid chromatography using solid-phase extraction. Journal of Chromatography B, 691, 179–185.
- BRESSOLLE, F., BROMET-PETIT, M. and AUDRAN, M., 1996, Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics. Journal of Chromatography B, 686, 3–10.
- CAUSON, R., 1997, Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. Journal of Chromatography B, 689, 175–180.
- DAWLS, M. R. and BAILLIE, T. A., 1995, Studies on the formation of reactive intermediates from the antineoplastic agent N,AP-bis(2-chloroethyl)-N-nitrosourea (BCNU) in vitro and in vivo. Characterization of novel glutathione adducts by ionspray tandem mass spectrometry. Journal of Mass Spectrometry, 30, 57–68.
- DONEHOWE R., ELZA-BROWN, K., O'REILLY, S., ISRAEL, B. and OROCHOW, L., 1998, A phase I dose escalation, safety, tolerability, and pharmacokinetic study of TAS-103 in patients with refractory solid tumors. Proceedings of the American Society of Clinical Oncology, 17, 209a.
- KASSAHUN, K., DAvis, M., Hu, P., MARTIN, B. and BAILLIE, T., 1997, Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. Chemical Research in Toxicology, 10, 1228–1233.
- KONDO, T., YOSHIDA, K., YOSHIMURA, Y., MOTOHASHI, M. and TANAYAMA, S., 1996, Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats byliquid chromatography/electro spray tandem mass spectrometry following chemicalderivatization. Journal of Mass Spectrometry, 31, 873–878.
- LAW, B. and STAFFORD, L. E., 1993, The use of ultraviolet spectra and chromatographic retention data as an aid to metabolite identification. Journal of Pharmaceutical and Biomedical Analysis, 11, 729–736.
- SUNAMI, T., NISHIO, K., KANZAWA, F., FUKUOKA, K., KUDOH, S., YOSHIKAWA, J. and SAIJO, N., 1999, Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells. Cancer Chemotherapy and Pharmacology, 43, 394–401.
- UTSUGI, T., ÄOYAGI, K., ASA°, T., OKAZAKI, S., filOYAGI, Y., SANO, M., WIERZBA, K. and YAMADA, Y., 1997, Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Japanese Journal of Cancer Research, 88, 992–1002.
- VICKERS, S., DUNCAN, C. A., SLAUGHTER, D. E., ÄRISON, B. H., GREBER, T., OLAH, T. V. and VYAS, K. P., 1998, Metabolism of MK-499, a class III antiarrhythmic agent, in rats and dogs. Drug Metabolism and Disposition, 26, 388–395.